Benjamin A Steinberg1, DaJuanicia N Holmes2, Karen Pieper2, Larry A Allen3, Paul S Chan4, Michael D Ezekowitz5, James V Freeman6, Gregg C Fonarow7, Bernard J Gersh8, Elaine M Hylek9, Peter R Kowey10, Kenneth W Mahaffey10, Gerald Naccarelli11, James Reiffel12, Daniel E Singer13, Eric D Peterson2,14, Jonathan P Piccini2,15. 1. Division of Cardiovascular Medicine, University of Utah Health Sciences Center, Salt Lake City, (B.A.S.). 2. Duke Clinical Research Institute, Durham, NC (D.N.H., K.P., E.D.P., J.P.P.). 3. Division of Cardiology & Colorado Cardiovascular Outcomes Research Consortium, University of Colorado School of Medicine, Aurora (L.A.A.). 4. Saint Luke's Mid America Heart Institute & Department of Medicine, University of Missouri-Kansas City, MO (P.S.C.). 5. Thomas Jefferson Medical College, Lankenau Medical Center, Wynnewood, PA (M.D.E.). 6. Yale University School of Medicine, New Haven, CT (J.V.F.). 7. UCLA Division of Cardiology, Los Angeles, CA (G.C.F.). 8. Mayo Clinic, Rochester, MN (B.J.G.). 9. Boston University School of Medicine, MA (E.M.H.). 10. Lankenau Institute for Medical Research, Wynnewood, PA (P.R.K.). 11. Stanford University School of Medicine, Palo Alto, CA (K.W.M.). 12. Penn State University School of Medicine, Hershey, PA (G.N.). 13. Columbia University College of Physicians and Surgeons, NY (J.R.). 14. Harvard Medical School & Massachusetts General Hospital, Boston, MA (D.E.S.). 15. Duke University Medical Center, Durham, NC (E.D.P., J.P.P.).
Abstract
BACKGROUND: Atrial fibrillation (AF) adversely impacts health-related quality of life (hrQoL). While some patients demonstrate improvements in hrQoL, the factors associated with large improvements in hrQoL are not well described. METHODS: We assessed factors associated with a 1-year increase in the Atrial Fibrillation Effect on Quality-of-Life score of 1 SD (≥18 points; 3× clinically important difference), among outpatients in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation I registry. RESULTS: Overall, 28% (181/636) of patients had such a hrQoL improvement. Compared with patients not showing large hrQoL improvement, they were of similar age (median 73 versus 74, P=0.3), equally likely to be female (44% versus 48%, P=0.3), but more likely to have newly diagnosed AF at baseline (18% versus 8%; P=0.0004), prior antiarrhythmic drug use (52% versus 40%, P=0.005), baseline antiarrhythmic drug use (34.8% versus 26.8%, P=0.045), and more likely to undergo AF-related procedures during follow-up (AF ablation: 6.6% versus 2.0%, P=0.003; cardioversion: 12.2% versus 5.9%, P=0.008). In multivariable analysis, a history of alcohol abuse (adjusted OR, 2.41; P=0.01) and increased baseline diastolic blood pressure (adjusted OR, 1.23 per 10-point increase and >65 mm Hg; P=0.04) were associated with large improvements in hrQoL at 1 year, whereas patients with prior stroke/transient ischemic attack, chronic obstructive pulmonary disease, and peripheral arterial disease were less likely to improve (P<0.05 for each). CONCLUSIONS: In this national registry of patients with AF, potentially treatable AF risk factors are associated with large hrQoL improvement, whereas less reversible conditions appeared negatively associated with hrQoL improvement. Understanding which patients are most likely to have large hrQoL improvement may facilitate targeting interventions for high-value care that optimizes patient-reported outcomes in AF. Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01165710.
BACKGROUND:Atrial fibrillation (AF) adversely impacts health-related quality of life (hrQoL). While some patients demonstrate improvements in hrQoL, the factors associated with large improvements in hrQoL are not well described. METHODS: We assessed factors associated with a 1-year increase in the Atrial Fibrillation Effect on Quality-of-Life score of 1 SD (≥18 points; 3× clinically important difference), among outpatients in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation I registry. RESULTS: Overall, 28% (181/636) of patients had such a hrQoL improvement. Compared with patients not showing large hrQoL improvement, they were of similar age (median 73 versus 74, P=0.3), equally likely to be female (44% versus 48%, P=0.3), but more likely to have newly diagnosed AF at baseline (18% versus 8%; P=0.0004), prior antiarrhythmic drug use (52% versus 40%, P=0.005), baseline antiarrhythmic drug use (34.8% versus 26.8%, P=0.045), and more likely to undergo AF-related procedures during follow-up (AF ablation: 6.6% versus 2.0%, P=0.003; cardioversion: 12.2% versus 5.9%, P=0.008). In multivariable analysis, a history of alcohol abuse (adjusted OR, 2.41; P=0.01) and increased baseline diastolic blood pressure (adjusted OR, 1.23 per 10-point increase and >65 mm Hg; P=0.04) were associated with large improvements in hrQoL at 1 year, whereas patients with prior stroke/transient ischemic attack, chronic obstructive pulmonary disease, and peripheral arterial disease were less likely to improve (P<0.05 for each). CONCLUSIONS: In this national registry of patients with AF, potentially treatable AF risk factors are associated with large hrQoL improvement, whereas less reversible conditions appeared negatively associated with hrQoL improvement. Understanding which patients are most likely to have large hrQoL improvement may facilitate targeting interventions for high-value care that optimizes patient-reported outcomes in AF. Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01165710.
Entities:
Keywords:
atrial fibrillation; cardiac resynchronization therapy; health status; patient-reported outcomes; quality of life
Authors: P Dorian; W Jung; D Newman; M Paquette; K Wood; G M Ayers; J Camm; M Akhtar; B Luderitz Journal: J Am Coll Cardiol Date: 2000-10 Impact factor: 24.094
Authors: Jonathan P Piccini; Elizabeth S Fraulo; Jack E Ansell; Gregg C Fonarow; Bernard J Gersh; Alan S Go; Elaine M Hylek; Peter R Kowey; Kenneth W Mahaffey; Laine E Thomas; Melissa H Kong; Renato D Lopes; Roger M Mills; Eric D Peterson Journal: Am Heart J Date: 2011-10 Impact factor: 4.749
Authors: James A Reiffel; Peter R Kowey; Robert Myerburg; Gerald V Naccarelli; Douglas L Packer; Craig M Pratt; Michael J Reiter; Albert L Waldo Journal: Am J Cardiol Date: 2010-02-20 Impact factor: 2.778
Authors: Oussama M Wazni; Nassir F Marrouche; David O Martin; Atul Verma; Mandeep Bhargava; Walid Saliba; Dianna Bash; Robert Schweikert; Johannes Brachmann; Jens Gunther; Klaus Gutleben; Ennio Pisano; Dominico Potenza; Raffaele Fanelli; Antonio Raviele; Sakis Themistoclakis; Antonio Rossillo; Aldo Bonso; Andrea Natale Journal: JAMA Date: 2005-06-01 Impact factor: 56.272
Authors: Michael T Durheim; DaJuanicia N Holmes; Rosalia G Blanco; Larry A Allen; Paul S Chan; James V Freeman; Gregg C Fonarow; Alan S Go; Elaine M Hylek; Kenneth W Mahaffey; Sean D Pokorney; James A Reiffel; Daniel E Singer; Eric D Peterson; Jonathan P Piccini Journal: Heart Date: 2018-06-06 Impact factor: 5.994
Authors: Daniel B Mark; Kevin J Anstrom; Shubin Sheng; Jonathan P Piccini; Khaula N Baloch; Kristi H Monahan; Melanie R Daniels; Tristram D Bahnson; Jeanne E Poole; Yves Rosenberg; Kerry L Lee; Douglas L Packer Journal: JAMA Date: 2019-04-02 Impact factor: 56.272
Authors: Carina Blomström-Lundqvist; Sigfus Gizurarson; Jonas Schwieler; Steen M Jensen; Lennart Bergfeldt; Göran Kennebäck; Aigars Rubulis; Helena Malmborg; Pekka Raatikainen; Stefan Lönnerholm; Niklas Höglund; David Mörtsell Journal: JAMA Date: 2019-03-19 Impact factor: 56.272
Authors: Paul Dorian; Caroline Burk; Christopher M Mullin; Rosemary Bubien; Donna Godejohn; Matthew R Reynolds; Dhanunjaya R Lakkireddy; Alan P Wimmer; Anil Bhandari; John Spertus Journal: Am Heart J Date: 2013-07-01 Impact factor: 4.749